Alterity Therapeutics Limited

Alterity Therapeutics Limited (ASX:ATH)

Offer Price

A$0.0110

per share

Offer Size

A$40,000,000

Open Now!
Apply Now

Placement

Alterity Therapeutics Limited (ASX:ATH)

ATH

Lead Manager

Offer Price

A$0.0110

per share

Offer Size

A$40,000,000

Placement

Alterity Therapeutics Limited

Offer Details

Issue Price (Per Share)

A$0.0110

Offer Size

A$40,000,000

Shares Available

3,636,363,636

Two-Tranche Institutional Placement via the issue of up to approximately 3.64 billion fully paid ordinary shares in the Company on the ASX (“New Shares”) seeking to raise up to approximately A$40.0 million (the “Placement” or the "Offer").  

  • Tranche 1 will be unconditional and in accordance with ASX L.R. 7.1 & 7.1A to raise approximately A$12.8 million by the issue of approximately 1.2 billion New Shares (“Tranche 1”).
  • Tranche 2 will be conditional, subject to shareholder approval to be sought at an extraordinary general meeting (EGM) to raise an additional up to approximately A$27.2 million by the issue of approximately 2.5 billion New Shares (“Tranche 2”). 

  At its sole discretion, the Company reserves the right to raise additional funds under the Placement (“Oversubscriptions”). Any Oversubscriptions will be offered under Tranche 2, subject to the receipt of shareholder approval.

The Placement is not underwritten.

Company Overview

Alterity is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and has recently completed its randomized, double blind, placebo controlled Phase 2 trial in Multiple System Atrophy (MSA). MSA is a devastating orphan disease without approved therapy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA.

Use of Funds

Funds will be used to accelerate regulatory activities, clinical and non-clinical development, and manufacture of drug to advance ATH434 following recent release of its positive Phase 2 results in MSA. Funds will also be used to commence a business development process for potential partnering and to continue research and discovery of novel compounds to treat major indications such as Parkinson’s disease.

Indicative Timetable

Trading halt

Pre-Market Thursday, 6 February 2025

Book closes for receipt of firm and irrevocable bids

10.00AM (AEDT) Friday, 7 February 2025

Confirmation letters returned to MST Financial

2.00PM (AEDT) Friday, 7 February 2025

Trading halt lifted and shares in the Company recommence trading on ASX

Monday, 10 February 2025

Settlement of Tranche 1

Friday, 14 February 2025

Allotment of New Shares under Tranche 1

Monday, 17 February 2025

Expected EGM

Late March 2025

Expected Settlement of Tranche 2

Late March 2025

Expected allotment of New Shares under Tranche 2, subject to receipt of shareholder approval

Late March 2025

Expected Allotment of New Options, subject to receipt of shareholder approval

Late March 2025

Disclaimer

This site does not constitute an offer, recommendation, or invitation to any person, nor does it purport to provide all of the information an interested party may require in order to investigate the affairs of Alterity Therapeutics Limited. This site is provided for information only and has not been prepared with the intention that the recipient should rely on it. Liquidity Technology Pty Ltd ("Liquidity") does not make any representation in relation to the contents of this site or give any assurances as to the accuracy or the degree of care or diligence used in preparing this document. The information, data, and advice herein is provided to recipients on the clear understanding that Liquidity nor any of its representatives, directors, officers, employees, agents, or advisers makes any representation or warranty about its accuracy, reliability, completeness, or suitability for any particular purpose and does not accept liability (including, but not limited to, for any expenses, losses, damages, and/or costs (including, but not limited to, indirect or consequential damage)) nor take any responsibility of any kind whatsoever (including, but not limited to, whether in contract, tort, financial or otherwise) for the information, data, or advice contained in or for any omission or for any other information, statement, or representation provided to any recipient (including, but not limited to, as a result of information, data, or advice being inaccurate, unreliable, incomplete, or unsuitable in any way and for any reason whatsoever). Users of this site must conduct their own investigation and analysis regarding any information, statement, or representation contained or provided to any recipient or its associates by Liquidity or any of the Liquidity Personnel. Each recipient waives any right of action, which it has now or in the future against Liquidity or any of the Liquidity Personnel in respect of any errors or omissions on or from this site, however caused. All rights are reserved. If the whole or any part of a provision of this "Notice and Disclaimer" is invalid, illegal, or unenforceable, then such provision will be severed and neither that part or provision or its severance will affect the validity or enforceability of the remaining parts or provisions.

Disclosure of Interest: Liquidity receives commission from dealing in securities and its introducers of business may directly share in this commission. Liquidity and its associates may hold shares in Alterity Therapeutics Limited.

Alterity Therapeutics Limited

Placement

Alterity Therapeutics Limited (ASX:ATH)

ATH

Offer Price

A$0.0110

per share

Offer Size

A$40,000,000

Cancel

I am a sophisticated 708 investor and agree to the terms and conditions

Alterity Therapeutics Limited

Follow Alterity Therapeutics Limited

By submitting your information below you can keep up to date with their relevant news and announcements.

Fields marked with * are required.

Name(Required)

Cancel

Alterity Therapeutics Limited

Ask Alterity Therapeutics Limited a question

Ask the company directors a question to understand more about their offering.

Fields marked with * are required.

Name(Required)

Cancel

Alterity Therapeutics Limited

Submit your details below to get access to the product documents and invest.

Cancel